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Abstract
Background: The prognostic value of hemoglobin A1c (HbA1c) in coronary artery disease (CAD) remains
controversial. Herein, we conducted a systematic review to quantify the association between elevated HbA1c levels
and all-cause mortality among patients hospitalized with CAD.
Methods: A systematic search of electronic databases (PubMed, EMBASE, OVID, Web of Science, The Cochrane
Library) for studies published from 1970 to May 2011 was performed. Cohort, case-control studies, and randomized
controlled trials that examined the effect of HbA1c on all-cause mortality were included.
Results: Twenty studies met final inclusion criteria (total n = 13, 224). From the pooled analyses, elevated HbA1c
level was significantly associated with increased short-term (OR 2.32, 95% CI, 1.61 to 3.35) and long-term (OR 1.54,
95% CI, 1.23 to 1.94) mortality risk. Subgroup analyses suggested elevated HbA1c level predicted higher mortality
risk in patients without diabetes (OR 1.84, 95% CI, 1.51 to 2.24). In contrast, in patients with diabetes, elevated
HbA1c level was not associated with increased risk of mortality (OR 0.95, 95% CI, 0.70 to 1.28). In a risk-adjusted
sensitivity analyses, elevated HbA1c was also associated with a significantly high risk of adjusted mortality in
patients without diabetes (adjusted OR 1.49, 95% CI, 1.24 to 1.79), but had a borderline effect in patients with
diabetes (adjusted OR 1.05, 95% CI, 1.00 to 1.11).
Conclusions: Our findings demonstrate that elevated HbA1c level is an independent risk factor for mortality in
CAD patients without diabetes, but not in patients with established diabetes. Prospective studies should further
investigate whether glycemic control might improve outcomes in CAD patients without previously diagnosed
diabetes.
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Background
In recent years, much attention has been paid to the
glycometabolism in patients with coronary artery disease
(CAD). Numerous prior studies have shown that ele-
vated admission or fasting glucose increases the risk of
death and in-hospital complications in patients with
acute coronary syndrome (ACS) and patients under-
going coronary revascularization [1-5].
Hemoglobin A1c (HbA1c) level is an indicator of aver-
age blood glucose concentrations over the preceding 2-3
months, which is a convenient and well-known biomar-
ker in clinical practice. Epidemiological evidence now
suggests that HbA1c level is an independent risk factor
for cardiovascular events in primary and secondary
populations [6-9]. Recently, an International Expert
Committee Report (IECR) recommended using the
HbA1c assay as the preferred method for diabetes diag-
nosis and suggested the diagnosis if the HbA1c level is
≥6.5% [10]. However, the prognostic value of HbA1c
level in patients with coronary atherosclerotic disease
has not been well characterized, and these studies that
examined this relationship have reported conflicting
results [11-23].
* Correspondence: yymwin@yahoo.com.cn
Institution of all authors: Emergency Department, Cardiovascular Institute
and Fuwai Hospital; Chinese Academy of Medical Sciences & Peking Union
Medical College, (167 Beilishilu Road), Beijing, (100037), China
Liu et al. Cardiovascular Diabetology 2011, 10:98
http://www.cardiab.com/content/10/1/98
CARDIO
VASCULAR 
DIABETOLOGY
© 2011 Liu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.To comprehensively analyze these data, we performed
a systematic review to examine whether an association
exists between elevated HbA1c and all-cause mortality
in patients hospitalized with CAD.
Methods
The methods for this meta-analysis are in accordance
with “Meta-Analysis of Observational Studies in Epide-
miology: A Proposal for Reporting.” [24]
Search strategy
A systematic search of publications listed in the electro-
nic databases (Medline via PubMed, EMBASE, OVID,
Web of Science, The Cochrane Library) from 1970 to
May 2011 were conducted using the following key
words in combination as both MeSH terms and text
words: ("coronary artery disease” or “acute coronary syn-
drome” or “acute myocardial infarction” or “percuta-
neous coronary intervention” or “coronary artery bypass
grafting”) and ("glycated hemoglobin” or “hemoglobin
A1c” or “HbA1c”). Language restrictions were not
applied, but our search was limited to human studies.
The list of articles was reviewed independently by two
authors. In addition, a manual review of references from
primary or review articles was performed to identify any
additional relevant studies
Study selection
Cohort, case-control studies, and randomized controlled
trials were included if they investigated the influence of
HbA1c on all-cause mortality in patients admitted with
CAD. The IECR recommended that HbA1c level > 6.5%
would be the cut-off value for diagnosis of diabetes [10].
In patients with diabetes, the American Diabetes Asso-
ciation (ADA) recommended HbA1c < 7% is associated
with a lower risk of diabetes-associated complications
[25]. We anticipated that not all studies would use
HbA1c value 6.5% or 7% as the cut-off point. Therefore,
in order to avoid eliminating studies with important
information, we considered HbA1c cut-off within the
range of 5% - 8% to be acceptable.
After obtaining full reports of candidate studies, the
same reviewers independently assessed eligibility. Differ-
ences in data between the two reviewers were resolved
by reviewing corresponding articles, and the final set
was agreed on by consensus. If the publications did not
contain the full information necessary for meta-analysis,
we obtained the missing information directly from the
authors (see Acknowledgments).
Quality assessment and data abstraction
Each study was evaluated for quality according to the
guidelines provided by the United States Preventive
Task Force [26] and published recommendations [27].
The following characteristics were assessed: (1) descrip-
tion of patient sample characteristics; (2) clear inclusion
and exclusion criteria; (3) potential selection bias; (4) a
priori definition of study outcomes; (5) completeness of
follow-up; (6) adjustment of possible confounders in
multivariate analysis; (7) explanation of sample selection;
and (8) timing of determination (whether HbA1c mea-
sured at baseline). Studies were graded as poor quality if
they met ≤4 criteria, fair if they met 5 to 6 criteria, and
good if they met ≥7 criteria.
For each study, the following data were extracted: first
author’s last name, the publication year, study design,
the sample size, study population, baseline characteris-
tics, length of follow-up, timing of HbA1c measurement,
cut-off value of HbA1c, variables adjusted for in the
multivariate statistical analysis, mortality data among
patients with and without elevated HbA1c level, and
adjusted mortality hazard ratios (HRs) with their 95%
CIs if possible.
Statistical analyses
We used REVMAN software (version 5.0; Cochrane
Collaboration, Oxford, United Kingdom) and Stata soft-
ware (version 11.0; Stata Corporation, College Station,
TX) to pool data for all outcomes. Firstly, unadjusted
short and long term all-cause mortality data were
extracted and pooled to calculate odds ratio (OR) and
95% CI using a random effects model for dichotomous
outcomes. Relative risks were also calculated separately
for diabetic and non-diabetic patients when possible.
Secondly, we performed baseline risk-adjusted analyses
to determine if our main results were robust when
quantitative pooling was limited to those studies in
which we could calculate pooled adjusted all-cause mor-
tality ORs. Heterogeneity was assessed visually using
Cochran’s c
2 statistics and the I
2 statistics. A random-
effect model of DerSimonian and Laird was applied to
calculate overall differences. Publication bias was esti-
mated using a funnel plot of study results against study
precision. We tested symmetry of the funnel plot using
the Egger’s test. P value was considered statistically sig-
nificant at < 0.05.
Results
Study selection
Our initial search yielded 1883 potential literature cita-
tions. Of these, 1844 were excluded after scanning titles
and abstracts, leaving 39 citations for full text assess-
ment. Of these, 20 studies with a total of 13, 224
patients met the inclusion criteria and were used for
this meta-analysis [13-23,28-36]. The remaining studies
were excluded largely because they did not include mor-
tality as an outcome or did not provide mortality data
according to HbA1c level; other subjects were included
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unusable format (mean and SDs for patients with and
without mortality). Additional data were requested from
the authors of three studies [11,12,19] but obtained for
only one study [19].
Characteristics of the trials
Baseline characteristics of the 20 studies included are
shown in Additional file 1 and six studies were retro-
spective [19,22,28,32,33,36]. We found no randomized
controlled trial that examined the effect of HbA1c on
mortality in patients admitted with CAD. Demographic
features of study populations (age, gender) were similar
across the studies, and the average age of the patients
ranged from 56 to 75 years. The study population
included 5258 patients (40%) admitted with AMI or
ACS, 4948 (37.4%) patients who underwent CAGB and
2990 patients (22.6%) underwent PCI. Five of the 20 stu-
dies investigated short-term (less than 3 months) all-
cause mortality [28-30,34,36], 13 studies reported long-
term (1 year to 8 years) mortality [13-20,22,23,32,33,35]
and 2 studies with both short and long-term follow-up
results [21,31]. All studies were of high methodological
quality (good or fair) (Additional file 1).
Table 1 shows baseline characteristics and treatment
of the patients in original articles according to HbA1c
level. As expected, patients with elevated HbA1c level
had a higher prevalence of comorbidities including
hypertension, heart failure, previous MI and renal insuf-
ficiency. Use of angiotensin-converting enzyme (ACE)
inhibitors, b-blockers and lipid lowering drugs was
higher in patients with elevated HbA1c compared to
those with normal HbA1c level.
Six studies [13,16,18,21,22,28] exclusively examined
non-diabetic patients, and the other six studies studied
diabetes alone [14,15,32,33,35,36], the percent of
diabetic patients was not reported in two studies [19,30]
and the rest incorporated patients with and without dia-
betes [17,20,23,29,31,34]. Diabetes status was assigned
on the basis of a history of diabetes or treatment with
hypoglycemic agents in 10 studies [14,15,17,20,23,29,
31,32,34,35]; in three of these studies, an elevated
HbA1c [35] or plasma glucose [14,17,35] was also used
to define newly diagnosed diabetes for patients without
diabetes history. The definition of diabetes was not spe-
cified in two studies [33,36].
HbA1c and risk of mortality
Nineteen studies reported all-cause mortality data
according to HbA1c levels [13,15-23,28-36] (Figure 1).
Analyses of the crude mortality revealed that 14.1% of
patients with elevated HbA1c level died compared with
11.7% of those with normal HbA1c. This translated into
an unadjusted mortality risk of OR 1.68 (95% CI, 1.38 to
2.06) in patients with elevated HbA1c. There was mod-
erate statistical heterogeneity among the studies (I
2 =
49%, p < 0.001). We found no evidence of publication
bias based on funnel plot or using the Egger’st e s t( P=
0.089). Subgroup analyses showed in the short-term fol-
low up cohort, the elevated HbA1c level was associated
with a more than two-fold increased risk of mortality
(OR 2.32, 95% CI, 1.61 to 3.35), with no evidence for
overall heterogeneity (I
2 = 0%, p = 0.48). Whereas
patients with higher HbA1c level had a 54% increased
risk of long-term mortality (OR 1.54, 95% CI, 1.23 to
1.94). And there was no significant difference between
the short-term and long-term results (p = 0.06 for sub-
group difference).
In addition, we performed a subgroup analyses to com-
pare the association between HbA1c and mortality in
patients with and without diabetes. These analyses were
restricted to the 12 studies in which separate mortality
Table 1 Baseline characteristics of the study population according to HbA1c
Baseline Characteristics Patients With Elevated HbA1c Patients With Normal HbA1c
Age (y), studies = 12, n = 10734 64 65
Male (%), studies = 12, n = 10734 64 72
History of Hypertension (%),
studies = 10, n = 10242
74 59
History of Heart failure (%),
studies = 4, n = 5276
22 14
Previous MI (%), studies = 3, n = 4219 48 24
Hyperlipidemia (%), studies = 3, n = 4149 36 35
Smoker (%), studies = 7, n = 3770 40 41
Body mass index (kg/m2), studies = 6, n = 2990 27 29
Renal insufficiency (%), studies = 5, n = 5806 10 7
b-Blocker (%), studies = 4, n = 3794 77 77
Angiotensin-converting enzyme (ACE) inhibitors (%), studies = 3, n = 1448 53 39
Lipid lowering drugs (%), studies = 4, n = 3794 67 41
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[13,15,16,18,21-23,28,32,33,35,36] (Figure 2). In patients
without diabetes, elevated HbA1c was associated with a
84% increased risk of mortality (OR 1.84, 95% CI, 1.51 to
2.24). While in patients with diabetes, elevated HbA1c
level was not associated with a significantly higher risk of
mortality (OR 0.95, 95% CI, 0.70 to 1.28).
Risk adjusted analyses
Eight studies used a Cox proportional hazards regres-
sion model to adjust for other prognostic factors to
determine independent association of HbA1c with mor-
tality [14,15,20-23,34,35] (Figure 3). All studies adjusted
for age and gender. Other covariates adjusted for
included diabetes [14,20,23], hypertension [14,15,22,23],
hyperlipidemia [14,20,22,33], heart failure [14,15,22,23],
smoker [14,15,22,23,35], arrhythmia [22,23], previous
CAD [14,15,20,22], multivessel disease [15,20,21], renal
function [22,23,35], peripheral vascular disease [23], and
study treatment [22]. In patients without diabetes, the
pooled analyses suggested elevated HbA1c was indepen-
dently associated with mortality after multivariate
Study or Subgroup
1.1.1 Short-term mortality
Oswald
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Halkos short
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Knapik
Cicek
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 4.55, df = 6 (P = 0.60); I² = 0%
Test for overall effect: Z = 4.50 (P < 0.00001)
1.1.2 Long-term mortality
Chowdhury
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Kragelunda
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Timmer
Gustafsson
Rasoul long
Alserius long
Halkos long
Matsuure
Lemesle
Tsuruta
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.08; Chi² = 27.73, df = 12 (P = 0.006); I² = 57%
Test for overall effect: Z = 3.72 (P = 0.0002)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.08; Chi² = 37.34, df = 19 (P = 0.007); I² = 49%
Test for overall effect: Z = 5.04 (P < 0.00001)
Test for subgroup differences: Chi²=3.43, df = 1( P= 0.06), I²=70.9%
Events
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272
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68
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0
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7
6
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6
146
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286
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5
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4098
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49
266
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537
2360
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11951
Weight
4.5%
4.4%
0.5%
4.9%
0.9%
3.0%
2.8%
21.1%
5.2%
7.0%
5.5%
2.6%
8.5%
5.0%
4.6%
9.9%
2.9%
4.8%
11.3%
8.8%
2.9%
78.9%
100.0%
M-H, Random, 95% CI
2.04 [0.95, 4.40]
2.31 [1.05, 5.07]
5.58 [0.31, 101.34]
2.04 [0.99, 4.17]
0.88 [0.11, 7.02]
1.84 [0.66, 5.13]
5.88 [2.03, 17.04]
2.32 [1.61, 3.35]
2.24 [1.13, 4.44]
1.14 [0.68, 1.91]
1.88 [0.97, 3.63]
2.89 [0.94, 8.86]
1.73 [1.15, 2.60]
1.09 [0.54, 2.21]
1.77 [0.83, 3.79]
1.77 [1.29, 2.42]
1.75 [0.62, 4.97]
3.05 [1.46, 6.37]
1.52 [1.22, 1.88]
Not estimable
0.66 [0.44, 0.97]
1.74 [0.61, 4.97]
1.54 [1.23, 1.94]
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Figure 1 Unadjusted risk of short and long term mortality based on elevated or normal HbA1c level.
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three studies combined data for diabetic and nondia-
betic patients, HbA1c level was also a predictor of mor-
tality independent of other prognostic factors (adjusted
OR 1.16, 95% CI, 1.03 to 1.30). But elevated HbA1c was
not significantly associated with adjusted risk of death in
diabetic patients (adjusted OR 1.05, 95% CI, 1.00 to
1.11). The overall pooled adjusted relative risk for ele-
vated HbA1c was OR, 1.10 (95% CI, 1.03 to 1.17) for all
the eight studies.
Discussion
The results of our meta-analysis suggest that elevated
HbA1c levels predict increased risk of short and long
term mortality in patients hospitalized with CAD. Sub-
group analyses showed that the impact of HbA1c on
mortality seemed to be different between patients with
and without diabetes. Elevated HbA1c was associated
with a higher risk of mortality in patients without recog-
nized diabetes even after adjusting for other known risk
factors, but had a neutral effect on mortality in patients
with diabetes.
Diabetes mellitus and acute glycemic control (admis-
sion, fasting or preoperative glucose level) are indepen-
dent prognostic factors for survival following ACS or
AMI [1-5,37,38]. Although acute hyperglycemia for
most patients may be a manifestation of antecedent dis-
turbed glucose metabolism [1,2], it is also partly caused
by the transient stress with release of catecholamines
and cortisol [39,40]. The adverse outcomes associated
with acute hyperglycemia may be somewhat attributed
to the stress response to a severe disease state. HbA1c
level is a stable indicator of unstressed long-term glu-
cose control and is more useful to predict the abnormal
Study or Subgroup
1.1.1 Diabetic patients
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Test for overall effect: Z = 6.09 (P < 0.00001)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.14; Chi² = 33.73, df = 11 (P = 0.0004); I² = 67%
Test for overall effect: Z = 2.73 (P = 0.006)
Test for subgroup differences: Chi²=13.17, df = 1( P= 0.0003), I²=92.4%
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8
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7
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14
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Total
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42
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29
7
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0
5
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29
6
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204
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1822
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Weight
12.4%
9.4%
4.7%
11.1%
4.6%
42.2%
7.5%
4.2%
12.0%
8.6%
10.8%
6.7%
7.9%
57.8%
100.0%
M-H, Random, 95% CI
0.89 [0.67, 1.18]
1.12 [0.67, 1.88]
1.86 [0.67, 5.19]
0.66 [0.44, 0.97]
Not estimable
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2.24 [1.13, 4.44]
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1.54 [0.86, 2.77]
1.73 [1.15, 2.60]
2.04 [0.95, 4.40]
2.12 [1.10, 4.06]
1.84 [1.51, 2.24]
1.46 [1.11, 1.92]
Elevated HbA1c Normal HbA1c Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Figure 2 Unadjusted risk of mortality for patients with or without diabetes based on elevated or normal HbA1c level.
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admission glucose [41]. However, recent studies that
evaluated the prognostic value of HbA1c in patients
hospitalized with advanced atherosclerosis have reported
discrepant results. Several studies showed that although
crude mortality data was higher in patients with elevated
HbA1c following adjustment for many cardiovascular
risk factors, HbA1c values failed to predict mortality
independently [11,15,16,20,30,36]. Others suggested that
HbA1c level was a potent predictor of in-hospital and
long-term death [13,14,21,23,29,31,34]. After systemati-
cally reviewing previous published data and directly
comparing the effect of HbA1 on outcomes in patients
with and without recognized diabetes, we found that
HbA1c levels had different prognostic effects based on
patient’s diabetes status.
There are several reasons for the discrepant findings
between patients with and without diabetes. First,
patients with elevated HbA1c but without known dia-
betes likely have diabetes that was neither diagnosed nor
treated, and other relevant cardiovascular risk factors
such as hypertension and dyslipidemia that were also
untreated before hospitalization; while those with dia-
betes are more likely to be treated with insulin and con-
trol the established risk factors [2,4]. This therapeutic
difference may account in part for the disparity in out-
comes. Second, the same cutoff value that defined ele-
vated HbA1c may have been relatively too low to
distinguish those with chronic hyperglycemia in diabetic
patients compared with in non-diabetic patients. Third,
recent studies suggested progress in the reperfusion
treatment of patients with AMI improved the outcome
of diabetic patients [42]. Effective reperfusion especially
PCI might attenuate the adverse effect of elevated
HbA1c on outcomes of diabetic patients [15]. Fourth,
HbA1c may lose its predictive power in diabetic patients
with heart failure as it has been recognized for other
cardiovascular risk factors like BMI and total cholesterol
[43]. A recent study reported the association between
mortality and HbA1C among 5815 diabetic patients
with heart failure appeared U-shaped, HbA1c ≤ 7.1 and
> 7.8% all associated with higher risk of death [44].
Another cohort study in diabetic patients with advanced
heart failure observed an inverse relationship between
Study or Subgroup
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Malmberg
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Subtotal (95% CI)
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Figure 3 Adjusted mortality risk ratio for elevated HbA1c level.
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present in ~20% of the diabetic patients included in our
analysis. Future studies should investigate the impact of
HbA1c in different high-risk diabetic populations with
CAD. Fifth, the UK Prospective Diabetes Study
(UKPDS) showed that although intensive glycemic treat-
ment resulted in a non-significant improvement in
macrovascular disease during the 5-year trial period
[46], the 10-year follow-up demonstrated a significant
risk reduction for myocardial infarction and death
emerged over time [47]. The follow-up periods for dia-
betic patients in our study were all less than five years.
Therefore, if the follow-up periods were longer, more
differences in the mortality between diabetic patients
with and without elevated HbA1c might have emerged.
Elevated HbA1c level is likely the result of long term
insulin resistance; metabolic disturbances associated
with insulin resistance including hyperglycemia, dyslipi-
demia, hypercoagulability and inflammation might the
major pathologic mechanism for the adverse impact of
elevated HbA1c in the setting of CAD [48]. In risk-
adjusted analysis, after adjusted for other prognostic fac-
tors such as old age, hypertension, prior myocardial
infarction, and hyperlipidaemia, HbA1c remained inde-
pendently associated with increased mortality risk
(except for patients with diabetes), but it was observed
that the associations were attenuated. This suggested
that the adverse effect of HbA1c on mortality is some-
what attributable to a correlation with other cardiovas-
cular risk factors. The presence of an elevated HbA1c
level, through its association with the metabolic syn-
drome, may potentially predate the development of
other risk factors, and hence these risk factors may
represent a common biological proatherogenic pathway
[49,50].
Prior clinical trials of intensive glucose control have
shown little benefit, and possibly some harm, of lower-
ing the HbA1c level in patients with diabetes to prevent
cardiovascular outcomes [46,47,51,52]. The results of
two recent meta-analyses suggested that intensive glu-
cose control reduced cardiovascular events with no
effect on mortality [53,54], and subgroup analyses
showed participants with a history of cardiovascular dis-
ease did not appear to benefit from intensive therapy
[54]. The majority of current trials for glycemic control
were designed primarily to patients with established dia-
betes. Our observation support the need for large rando-
mized trials designed to confirm or refute preliminary
suggestions that intensive glycemic control may improve
outcomes in CAD patients without diabetes and elevated
HbA1c level.
Several limitations of this meta-analysis should be
noted. First, the pooled studies differed in inclusion and
exclusion criteria, cutoffs for elevated HbA1c, definition
of diabetes, duration of follow-up and concomitant
treatment. These may be the major source of heteroge-
neity. We used a random effects model in an effort to
incorporate heterogeneity between trials in our analysis,
but recognize that this does not eliminate the fact that
heterogeneities were present. Second, given the lack of
data in some studies, less than half the studies were
combined for adjusted analysis, which meant that the
results of risk-adjusted analysis were less conclusive.
And the covariates adjusted in each study were different.
Given the limitations, the results should be interpreted
cautiously. Third, although we found no significant
effect of elevated HbA1c on all-cause mortality in
patients with diabetes, recent studies suggested that
HbA1c was associated with an increased risk of major
adverse cardiac events following stent implantation [55]
and was a predictor of ischemic events in diabetic
patients [56]. The prognostic effect of HbA1c on other
cardiovascular events in diabetic patients with CAD
needs further evaluation. Finally, given that a proportion
of studies included are retrospective, a possibility of resi-
dual confounding by unmeasured factors cannot be
eliminated. This provided associative, not causal, evi-
dence and mandates caution when interpreting these
results.
Conclusions
In conclusion, we found that HbA1c level is an indepen-
dent predictor of total mortality in CAD patients with-
out but not in patients with established diabetes.
Glycemic control, diabetes screening, and risk factor
modification may represent opportunities to improve
care in this group of patients.
Additional material
Additional file 1: Characteristics of selected studies. Additional file 1
shows baseline characteristics of the 20 studies included.
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